Real-world overall survival (OS) improvements in metastatic urothelial carcinoma (mUC) across three key therapeutic eras.Antonio Cigliola, Andrea Necchi, N. Agarwal et al.|Journal of Clinical Oncology|2026Cited by 1
<i>ERBB3</i> -altered clinically advanced urothelial bladder cancer: Genomic landscape study and therapeutic possibilities.Steven Blinka, Petros Grivas, Ruben Raychaudhuri et al.|Journal of Clinical Oncology|2026Cited by 0